Vertical: CNMBase Year: 2025
Market Size (2025)
$1.49B
Projected (2032)
$4.49B
CAGR (2022–2032)
17.2%
Key Players
11+
Market Overview
The Global RNAi Biopesticides Market was valued at USD 1,494.27 Million in 2025 and is projected to reach USD 4,493.03 Million by 2032, expanding at a CAGR of 16.98% over the forecast period 2026–2032. In absolute terms, the market is expected to add USD 2,998.76 Million between 2025 and 2032. Historically, the market grew from USD 920.16 Million in 2022 to USD 1,082.36 Million in 2023 and USD 1,272.23 Million in 2024, reflecting the transition of RNA interference (RNAi) crop protection from a technology confined to genetically engineered corn traits to a broader category that now includes registered sprayable double-stranded RNA (dsRNA) products.
RNAi biopesticides work by delivering dsRNA molecules that silence a gene essential to the survival or virulence of a specific pest or pathogen. Because the active sequence is designed against a target organism’s genome, these products offer a level of species specificity that conventional broad-spectrum chemistry cannot match. They also degrade rapidly in soil and water and introduce new modes of action into resistance-management programmes. The commercial milestones of the past few years underline this shift. In December 2023 the U.S. Environmental Protection Agency (EPA) registered ledprona (marketed as Calantha), the first sprayable dsRNA pesticide, for Colorado potato beetle. In September 2025 the EPA registered vadescana, an RNAi product for Varroa mite control in honeybee colonies. In parallel, the corn rootworm trait portfolio has expanded through new RNAi events registered by the EPA in 2024 and 2025.
Key Findings
Application Method: Sprayable (SIGS) was the largest segment in 2025 with USD 821.85 Million (55.00% share) and is also the fastest-growing segment, with a CAGR of 19.89% through 2032. Plant-Incorporated accounted for USD 672.42 Million (45.00%) and is projected to grow at 12.46%.
Target Pest: Insects was the largest segment in 2025 with USD 1,045.99 Million (70.00% share), while Diseases & Others is the fastest-growing segment at a CAGR of 19.67%.
Region: North America led the market in 2025 with USD 896.56 Million (60.00% share). Middle East & Africa is the fastest-growing region, with a CAGR of 21.12%, followed closely by Asia Pacific at 20.58%.
Country: The U.S. was the leading country in 2025 with USD 788.97 Million, while India is the fastest-growing country, with a CAGR of 23.84% over 2026–2032.
Shift in mix: Plant-Incorporated products accounted for 53.00% of the market in 2022. Sprayable (SIGS) products overtook them in 2024, and their share is projected to reach 66.00% by 2032.
Segmentation Summary
The market is analysed by Application Method (Sprayable (SIGS) and Plant-Incorporated), by Target Pest (Insects and Diseases & Others), and by Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa), with country-level analysis within each region. Sprayable (SIGS) products are expected to add USD 2,143.55 Million between 2025 and 2032, about 71.48% of the total absolute growth of the market. Several factors favour sprayable formats. They do not require the development, deregulation and seed multiplication of a genetically engineered crop event. They can be applied to crops where transgenic traits are not commercially accepted. And the dsRNA sequence can be redesigned more quickly as pest populations change. Insect control remains the core application, supported by commercial products for corn rootworm and Colorado potato beetle. The Diseases & Others segment is expanding faster as fungal, viral and mite targets progress through development and registration.
Competitive Landscape Summary
The market is at an early commercial stage and is concentrated at the product level, although participation is widening. Revenue in the plant-incorporated segment is generated mainly by Bayer Crop Science and Corteva Agriscience through RNAi-containing corn rootworm trait stacks such as SmartStax PRO, VT4PRO with RNAi Technology and Vorceed Enlist, and through trait licensing to other seed companies. In the sprayable segment, GreenLight Biosciences holds a first-mover position with EPA-registered products for Colorado potato beetle and Varroa mite. It also has a fungicide candidate under regulatory review in Brazil and other markets. Behind these leaders sits a group of platform developers that focus on lowering dsRNA production cost and improving field stability, often in partnership with established crop protection companies: AgroSpheres (with FMC Corporation), Renaissance BioScience (with Certis Belchim), RNAissance Ag, SenseUP, Genolution and Silicon Gene Technologies. Competition centres on sequence design and intellectual property, manufacturing cost per gram of dsRNA, formulation and delivery technology, and the ability to navigate regulatory pathways that are still being defined in several jurisdictions.
Challenges and Opportunities
The principal challenges are technical and regulatory. Naked dsRNA degrades quickly on leaf surfaces under ultraviolet light and rainfall. Uptake efficiency varies widely between pest groups and is notably weaker in many lepidopteran species. Production costs, although falling sharply, remain above those of many generic synthetic actives. Regulatory frameworks for sprayable dsRNA are mature in the U.S. but still emerging in the European Union, China, Brazil and India. The resulting differences in data requirements and timelines raise the cost of multi-country launches. Public perception of gene-silencing technologies is a further consideration in markets that are sensitive to genetic modification.
These challenges are matched by substantial opportunities. Withdrawals of synthetic active ingredients and rising resistance in key pests create demand for new modes of action. Specialty crops, including potatoes, grapes, fruits and vegetables, offer premium pricing and tolerance for targeted, residue-free solutions. Pollinator health is an adjacent market that has already produced a registered product. Encapsulation and microbial fermentation technologies are improving field persistence and economics. Emerging regulatory pathways in China and Brazil, together with the EU’s first emergency use of an RNA-based spray in 2026, indicate that access to large agricultural markets outside the U.S. is opening.
Future Outlook
The market is projected to grow from USD 1,753.64 Million in 2026 to USD 4,493.03 Million in 2032. Growth over the forecast period is expected to be led by Sprayable (SIGS) products, which are projected to reach USD 2,965.40 Million by 2032, and by faster adoption in Asia Pacific, Latin America and Middle East & Africa. Asia Pacific is projected to increase from USD 224.14 Million in 2025 to USD 844.69 Million in 2032, overtaking Europe, which is projected to reach USD 736.86 Million. North America will remain the largest regional market, at USD 2,354.35 Million in 2032, although its share is expected to decline as other regions scale. China (USD 304.09 Million in 2032) and Brazil (USD 280.92 Million in 2032) are expected to become the most significant markets outside the U.S. The coming years will likely see more registered active ingredients, combination products that pair dsRNA with biological or conventional partners, and wider licensing of RNAi traits.
The RNAi Biopesticides Market market is projected to grow at a CAGR of 17.2% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
RNAi biopesticides are crop protection products whose active ingredient is a double-stranded RNA (dsRNA), small interfering RNA (siRNA) or hairpin RNA molecule designed to trigger the RNA interference pathway in a target organism. When the target pest or pathogen takes up the RNA, it is processed by the organism’s own Dicer enzymes into short interfering fragments. These fragments guide the RNA-induced silencing complex (RISC) to degrade the matching messenger RNA. Silencing a gene essential for feeding, development, reproduction or infection leads to mortality, reduced fitness or suppression of disease. Because activity depends on sequence complementarity, a well-designed RNAi product acts only on the target species and close relatives.
For the purpose of this study, the market includes:
Sprayable (SIGS) products: externally applied dsRNA products delivered by foliar spray, soil application, trunk injection, seed treatment or hive treatment. This category, referred to as spray-induced gene silencing (SIGS), includes both naked and formulated or encapsulated dsRNA.
Plant-Incorporated products: plant-incorporated protectants (PIPs) in which a crop is engineered to express dsRNA or siRNA directed at a pest or pathogen (host-induced gene silencing). Corn rootworm traits such as DvSnf7 and DvSSJ1, and virus-resistance traits in potato, are examples. Value is attributed to the RNAi component of the trait offering.
Products targeting insects, as well as products targeting fungal, oomycete and viral diseases, mites (including Varroa mite in honeybee colonies), weeds and other pests.
The market excludes microbial biopesticides, biochemical pesticides (such as pheromones and plant extracts), peptide- and protein-based bioinsecticides (including Bt protein traits sold without an RNAi component), CRISPR- or other gene-edited crops whose protection does not rely on an RNAi active ingredient, and RNA-based products for human or veterinary therapeutics. Research services, contract dsRNA manufacturing sold for non-crop-protection uses, and seed value unrelated to the RNAi trait are also excluded.
Scope of the Study
This report provides historical data for 2022–2024, a base-year estimate for 2025 and forecasts for 2026–2032. All market values are in USD Million, and growth rates are expressed as compound annual growth rates (CAGR) for 2026–2032. The market is analysed across the following dimensions:
By Application Method: Sprayable (SIGS); Plant-Incorporated
By Target Pest: Insects; Diseases & Others
By Region: North America (U.S., Canada, Mexico); Europe (Germany, U.K., France, Italy, Spain, Rest of Europe); Asia Pacific (China, India, Japan, Rest of Asia Pacific); Latin America (Brazil, Argentina, Rest of Latin America); Middle East & Africa (UAE, Saudi Arabia, South Africa, Rest of MEA)
Each region and country is further analysed by Application Method and Target Pest. The study also profiles the competitive environment, covering key participants, their positioning and their strategic developments since 2022.
Research Objectives
To estimate and forecast the size of the global RNAi biopesticides market in value terms (USD Million) for 2022–2032.
To analyse the market by application method, distinguishing externally applied (sprayable) dsRNA products from plant-incorporated RNAi traits.
To assess demand by target pest category, covering insect control and disease and other pest applications.
To quantify regional and country-level market opportunities and identify the fastest-growing geographies.
To evaluate the drivers, restraints, opportunities, trends and challenges influencing adoption, including regulatory approvals and pest resistance dynamics.
To examine the regulatory pathways for dsRNA-based products and RNAi plant-incorporated protectants in major regions.
To analyse the value chain, from dsRNA manufacturing inputs to end-use growers and beekeepers.
To identify the leading companies and review their positioning, product portfolios and strategic developments from 2022 onward.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured, multi-stage research process. It began with a definition of the market scope and segmentation, followed by extensive secondary research to build an understanding of the technology, regulatory status, product pipeline and competitive landscape. Primary research with participants across the value chain then validated and refined the findings. Market size was estimated using both top-down and bottom-up approaches, and the results were triangulated. Finally, forecasts were developed by modelling the impact of identified market drivers and restraints over the forecast period. All estimates were reviewed for internal consistency across segments, regions and countries.
Secondary Research
Secondary research covered the following categories of sources relevant to RNAi-based crop protection:
Regulatory and government bodies: pesticide and biotechnology registration records and decision documents from agencies such as the U.S. EPA (pesticide product labels, registration decisions and plant-incorporated protectant listings), USDA APHIS, the European Food Safety Authority, the European Commission, Health Canada, Brazil’s Ministry of Agriculture and Livestock (MAPA) and CTNBio, India’s Central Insecticides Board and Registration Committee, and China’s Institute for the Control of Agrochemicals, Ministry of Agriculture and Rural Affairs (ICAMA).
International and intergovernmental organisations: OECD guidance on the risk assessment of dsRNA-based pesticides, FAO pest and pesticide management resources, and ISO common-name decisions for new active ingredients.
Industry associations: publications from crop protection and biological industry associations, and resistance-management bodies such as the Insecticide Resistance Action Committee (IRAC).
Company sources: annual reports, financial filings, investor presentations, press releases and product labels of trait developers, crop protection companies and RNAi platform start-ups.
Trade journals and scientific literature: agricultural trade press, peer-reviewed literature on RNAi efficacy, delivery and environmental fate, and patent databases.
Paid databases: agrochemical market, crop area and pest-pressure databases, and company and funding databases.
Primary Research
Primary research was conducted through in-depth interviews with industry participants on both the supply and demand sides. Its aims were to validate market definitions and segment boundaries, verify pricing and adoption assumptions, gather qualitative insights on technology and regulatory trends, and test the forecast outlook.
Supply side: executives and technical managers at RNAi platform companies, crop protection and seed companies, contract dsRNA manufacturers, formulation specialists, and distributors and agricultural retailers.
Demand side: row-crop and specialty-crop growers, potato and grape producers, crop advisers and agronomists, seed dealers, commercial beekeepers, and procurement personnel at grower cooperatives.
Other experts: academic researchers in insect molecular biology and plant pathology, regulatory consultants, and resistance-management specialists.
Market Size Estimation
Top-down approach: The overall crop protection and biopesticide market was taken as the starting point and narrowed to the RNAi-based share. The share was derived from the adoption of RNAi-containing corn rootworm traits, the commercial uptake of registered sprayable dsRNA products, and the penetration of RNAi products in relevant crop–pest combinations in each region.
Bottom-up approach: Revenues attributable to RNAi products were estimated for leading companies and summed. These estimates were built from planted area of RNAi trait hybrids and the value attributable to the RNAi component, treated acreage and per-hectare pricing for sprayable products, and hive treatment volumes for bee-health applications. Country-level estimates were aggregated to regional and global totals.
Data triangulation: The results of the two approaches were compared and reconciled with insights from primary interviews. Remaining variances were resolved by weighting the most reliable data points, and segment, regional and country estimates were checked to sum to the overall market total.
Forecasting Methodology
Forecasts for 2026–2032 were developed with a driver-based model. Factors considered include the expected timing of new active-ingredient and trait registrations, the progression of products through late-stage development, the spread of resistance to existing chemistries, the pace of synthetic active ingredient withdrawals, trends in dsRNA manufacturing cost, crop area and pest pressure in each country, regulatory developments for dsRNA-based products, and grower adoption curves observed for comparable new technologies. Scenario analysis was used to test sensitivities around regulatory timing and manufacturing cost.
Base Year, Forecast Period and Currency
Historical years: 2022, 2023 and 2024
Base year: 2025
Forecast period: 2026–2032
CAGR period: 2026–2032
Currency: USD Million
Assumptions and Limitations
Market values are expressed in nominal USD and assume broadly stable exchange rates over the forecast period.
Regulatory frameworks are assumed to evolve along currently announced pathways, without abrupt restrictions on dsRNA-based products in major markets.
For plant-incorporated products, value is attributed to the RNAi component of trait offerings. Where traits are sold as bundled stacks, this attribution relies on analyst assessment.
Revenue for privately held companies is not publicly disclosed and has been estimated from indirect indicators.
Products currently in development are included in forecasts on a probability-adjusted basis. Delays or failures in registration could affect segment outcomes.
Macroeconomic conditions, commodity prices and weather-driven variation in pest pressure can cause year-to-year deviations from forecast values.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The RNAi biopesticides market is at an early stage of commercialisation and has a two-tier structure. In the Plant-Incorporated segment, the market is consolidated: two global seed and trait companies, Bayer Crop Science and Corteva Agriscience, account for most RNAi trait revenue through corn rootworm trait stacks, and Bayer also licenses its RNAi traits to other seed companies. In the Sprayable (SIGS) segment, the market is fragmented and developing. GreenLight Biosciences is the only company with multiple registered sprayable dsRNA products, while a growing group of venture-backed platform developers and research spinouts is advancing pipelines across insects, fungal diseases, viruses and mites.
Competition rests less on price than on technology. The key factors are sequence design and target selection, intellectual property, dsRNA manufacturing cost, formulation for field stability, and regulatory expertise. Partnerships are central to competitive strategy. Large agrochemical companies such as FMC and Certis Belchim are accessing RNAi through co-development agreements with specialist developers rather than through acquisitions, while start-ups rely on these partners for field testing, registration and distribution. Corporate restructuring among the majors, including Corteva’s planned separation of its seed and crop protection businesses and FMC’s review of strategic options announced in 2026, may reshape partnership and licensing arrangements over the forecast period.
Key Player Positioning
Leaders: Bayer Crop Science, Corteva Agriscience and GreenLight Biosciences.
Bayer Crop Science (Crop Science division sales of approximately EUR 21.6 billion in FY2025) pioneered commercial RNAi in agriculture with SmartStax PRO, the first RNAi-based plant-incorporated protectant against an insect pest, registered by the U.S. EPA in 2017. Its portfolio includes VT4PRO with RNAi Technology and the next-generation MON 95275 event. Its strategy is to stack RNAi with Bt and other proteins for durable corn rootworm control and to license its traits across the seed industry.
Corteva Agriscience (net sales of USD 17.40 billion in FY2025) markets Vorceed Enlist corn, which includes an RNAi mode of action for below-ground protection, and has developed its own RNAi trait, DP23211, with DvSSJ1 dsRNA, registered by the U.S. EPA in 2024. Its strategy is to build proprietary RNAi traits into its own trait platforms and reduce its reliance on licensed technology.
GreenLight Biosciences (privately held; revenue not publicly disclosed) is the leader in sprayable dsRNA. It holds U.S. registrations for ledprona (Calantha) and vadescana (Norroa), has a fungicide, erysichrona, under regulatory review, and uses a proprietary cell-free RNA manufacturing platform. It is expanding into the EU, through its Seville centre and EIB financing, and into Brazil.
Challengers: FMC Corporation and AgroSpheres.
FMC Corporation (revenue of USD 3.47 billion in FY2025) is accessing RNAi technology through its partnership with AgroSpheres, contributing screening, development and go-to-market capabilities within its biologicals strategy. Two RNA bioinsecticide candidates from the partnership entered global field trials in 2026.
AgroSpheres (privately held; revenue not publicly disclosed) is a University of Virginia spinout whose AgriCell platform produces and encapsulates RNA and other bioactives to improve stability and cost. It is commercialising through partnerships with major agrochemical companies.
Niche players: J.R. Simplot Company, Renaissance BioScience, Genolution, Silicon Gene Technologies, RNAissance Ag and SenseUP.
J.R. Simplot Company (privately held) applies RNAi traits in its own potato varieties. Its BG25 potato with potato virus Y protection was registered by the U.S. EPA in July 2025.
Renaissance BioScience (privately held) is developing yeast-based RNAi biopesticides for Colorado potato beetle, flea beetles and wireworms, commercialising through partners such as Certis Belchim.
Genolution (listed on KOSDAQ; total revenue of KRW 9,404 million in FY2025) is a South Korean RNA company that produces dsRNA at scale and develops products for crop viral diseases and bee health.
Silicon Gene Technologies (privately held) is a Shanghai-based developer whose dsRNA virucide tomovircona, for tobacco mosaic virus, is among the first RNA pesticides in China’s registration process.
RNAissance Ag (privately held; a TechAccel subsidiary) is developing sprayable RNAi products, led by a programme for diamondback moth, and holds in-house RNA manufacturing capability.
SenseUP (privately held) is a Forschungszentrum Jülich spinout in Cologne developing encapsulated dsRNA produced by Corynebacterium fermentation for insect, fungal and viral targets.
Threat of New Entrants: Medium
Lower dsRNA production costs and accessible sequence-design tools have enabled several venture-backed start-ups to enter the market.
Lengthy and costly regulatory processes, strong patent positions held by incumbents, and the need for global distribution are significant barriers to reaching commercial scale.
Many new entrants therefore depend on partnerships with established agrochemical companies, which limits their independent threat.
Bargaining Power of Suppliers: Medium
Basic inputs such as nucleotides, enzymes and fermentation media are sourced from multiple chemical and life-science suppliers.
Large-scale, low-cost dsRNA manufacturing capacity remains limited, giving specialised producers some leverage over companies without in-house production.
Vertical integration by leading developers into manufacturing reduces supplier power over time.
Bargaining Power of Buyers: Medium
Growers and distributors are price-sensitive and can choose from a wide range of established crop protection products.
Where RNAi offers the only effective option against resistant pest populations, buyers have less leverage.
For trait products, RNAi value is bundled within seed pricing, which reduces direct price negotiation on the RNAi component.
Threat of Substitutes: High
Synthetic insecticides and fungicides remain widely available, often as low-cost generics.
Bt traits, microbial biopesticides, biochemicals, peptides and integrated pest management practices compete for the same pest-control budgets.
Gene-edited crop varieties with built-in resistance may emerge as alternatives to some plant-incorporated RNAi solutions in the long term.
Competitive Rivalry: Medium
The number of commercially registered RNAi products is still small, and leaders have differentiated positions in specific crop–pest combinations.
Rivalry is intensifying as pipelines mature, more companies file for registration and agrochemical majors partner with RNAi developers.
Competition is based increasingly on cost per hectare, field reliability and the breadth of target pests covered.
Threat of New Entrants: Medium; Platform start-ups can enter with novel sequences and production technologies; regulatory costs, IP barriers and the need for distribution partners limit scale.
Bargaining Power of Suppliers: Medium; Specialised dsRNA manufacturing capacity is concentrated among a small number of producers; enzyme, nucleotide and fermentation inputs are widely available.
Bargaining Power of Buyers: Medium; Growers are price-sensitive and have many alternatives; buyer power is lower where RNAi offers a unique solution for resistant pests or is bundled within seed.
Threat of Substitutes: High; Synthetic insecticides and fungicides, Bt traits, microbial and biochemical biopesticides, and cultural controls are well established and often cheaper.
Competitive Rivalry: Medium; A limited number of commercial products and players today; rivalry is increasing as pipelines mature and majors partner with RNAi developers.
Market estimates by geography (2032)
InsightNorth America leads with $2.35B by 2032, while Middle East & Africa is projected to grow fastest at a 22.3% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $599.03M | $1.18B | $2.35B | 14.7% | 52% |
| Europe | $126.98M | $318.11M | $736.86M | 19.2% | 16% |
| Asia Pacific | $115.94M | $334.97M | $844.69M | 22.0% | 19% |
| Latin America | $62.57M | $177.05M | $440.32M | 21.5% | 10% |
| Middle East & Africa | $15.64M | $45.24M | $116.82M | 22.3% | 3% |
| Total | $920.16M | $2.06B | $4.49B | 17.2% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$4.49B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Sprayable (SIGS) | $2.97B | 21.2% | 66% |
| Plant-Incorporated | $1.53B | 12.1% | 34% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on RNAi Biopesticides Market covering market dynamics, competitive landscape, and strategic outlook.
The RNAi Biopesticides Market market is projected to reach $4.49B by 2032, growing at 17.2% CAGR. The Sprayable (SIGS) segment holds the largest share.
The RNAi biopesticides market is shaped by agronomic, regulatory, technological and commercial forces. On the demand side, growers need new modes of action because key pests have developed resistance to existing chemistries and Bt traits, and because regulatory decisions have narrowed the toolbox of synthetic active ingredients. On the supply side, lower dsRNA manufacturing costs, advances in formulation, and partnerships between specialised RNAi developers and established agrochemical companies are broadening the product pipeline. Field stability, delivery efficiency in certain pest groups and uneven regulatory frameworks continue to moderate the pace of adoption.
Rising Resistance to Conventional Insecticides and Bt Traits
Resistance is one of the most important commercial drivers of RNAi adoption. The Colorado potato beetle has a well-documented history of resistance to a large number of insecticide classes, and growers in North America and Europe have seen control failures with several modes of action. The western corn rootworm has developed resistance to multiple Bt proteins in parts of the U.S. Corn Belt, which has eroded the performance of single-trait products. RNAi products bring a mechanism that is genuinely new to these pests. For example, the Insecticide Resistance Action Committee assigned ledprona to a new mode-of-action group (Group 35). RNAi traits for corn rootworm are being stacked with Bt proteins as a deliberate resistance-management strategy, as in SmartStax PRO, VT4PRO with RNAi Technology and Vorceed Enlist. Because RNAi products can be redesigned to target different genes in the same pest, they also offer a renewable source of new modes of action. This is a strong argument for growers, crop advisers and regulators managing resistance in high-value crops.
Regulatory Pressure on Synthetic Chemistries and Demand for Safer Inputs
Regulators in Europe, North America and parts of Asia have been reviewing and withdrawing older synthetic active ingredients over the past decade. In the EU, non-renewals under Regulation (EC) No 1107/2009 have removed a number of insecticides and fungicides, leaving gaps for specific crop–pest combinations. Retailers, food processors and consumers are also pushing for lower residues and reduced impacts on pollinators and aquatic life. RNAi biopesticides fit these requirements well: they are highly specific to the target organism, they degrade rapidly in the environment, and they leave no persistent residues of concern. In the U.S., the EPA has registered dsRNA products for both crop and pollinator-health uses, and it has established an exemption from the requirement of a tolerance for vadescana. These decisions provide a regulatory benchmark that other agencies can reference as they build their own frameworks.
Falling Cost of dsRNA Production
Historically, the cost of producing dsRNA at agricultural scale was a major barrier, since early laboratory methods were far too expensive for field use. Several manufacturing platforms have since reduced costs substantially: cell-free enzymatic synthesis (used by GreenLight Biosciences), microbial fermentation in bacteria and yeast (pursued by Renaissance BioScience, SenseUP and others), and fermentation combined with encapsulation (AgroSpheres). Investment is flowing into manufacturing capacity. In February 2025 the European Investment Bank agreed a loan of up to EUR 35 million to GreenLight Biosciences for research, registration and manufacturing activities in Spain. Lower production costs widen the range of crops where RNAi products are economically viable, from high-value potatoes and grapes towards broader-acre and lower-margin applications.
Expanding Pipeline Through Industry Partnerships and Investment
Established agrochemical companies are increasingly accessing RNAi technology through partnerships rather than building it in-house. FMC Corporation entered a multi-year research and co-development agreement with AgroSpheres in May 2024, and in September 2026 two RNA bioinsecticide candidates from the collaboration advanced into global field trials in the U.S., Brazil and Asia. Renaissance BioScience signed a joint development agreement with Certis Belchim in November 2023, and Genolution signed a memorandum of understanding with SB Sungbo in June 2025 covering dsRNA crop protection agents. Venture and climate-focused investors are also active: GreenLight raised a USD 25 million Series C in April 2025, AgroSpheres closed a USD 25 million Series B in December 2023, and SenseUP completed a seed round in 2025. These partnerships give RNAi developers access to global field-testing networks, regulatory expertise and distribution, which shortens the path from discovery to commercial sales.
Expansion into Fungal and Viral Disease Control
Disease control is a large addressable opportunity. Fungal pathogens such as grape powdery mildew, Botrytis and Fusarium, and viruses such as tobacco mosaic virus, tomato spotted wilt virus and potato virus Y, cause major losses in high-value crops. dsRNA products targeting fungal genes, and RNAi-based virus resistance, are now progressing towards market. GreenLight’s erysichrona for grape powdery mildew received an ISO common name in 2026 and has been filed for registration in Brazil. Silicon Gene Technologies’ tomovircona for tobacco mosaic virus has entered China’s registration process. In the U.S., Simplot’s BG25 potato, with RNAi-based PVY protection, was registered by the EPA in July 2025.
Pollinator Health and Non-Crop Applications
The EPA registration of vadescana in September 2025 for control of Varroa mites in honeybee colonies opened a new application area for RNAi products. Varroa mites and the viruses they transmit are a leading cause of honeybee colony losses, and beekeepers have limited treatment options because of mite resistance to several existing products. Species-specific RNAi solutions suit hive environments, where safety for non-target organisms is essential. Similar approaches can be extended to forestry pests, invasive species and other ecological settings where broad-spectrum chemistry is inappropriate.
Emerging Regulatory Pathways in High-Growth Agricultural Markets
Brazil, China and India have large agricultural sectors with intense pest pressure and growing interest in biological inputs. China’s draft data requirements for RNA pesticides and Brazil’s review of its first RNA-based spray registration filing point to clearer regulatory pathways in the coming years. Brazil’s 2023 pesticides law (Law No. 14,785/2023) restructured the registration process. India’s fast-growing biopesticide sector and the scale of its horticultural and cotton production make it an attractive long-term market. Companies that establish regulatory dossiers, local partnerships and field-trial data early in these markets are well placed to capture a large share of future growth.
Environmental Instability and Delivery Challenges
Naked dsRNA applied to plant surfaces is degraded by ultraviolet radiation, washed off by rain and broken down by microbial nucleases, so its window of activity in the field is limited. Uptake also varies considerably between pest groups. Beetles (Coleoptera) are generally highly sensitive to ingested dsRNA, while many caterpillars (Lepidoptera) and some sap-feeding insects are much less responsive because of gut nucleases and inefficient cellular uptake. These limits narrow the range of commercially viable targets and can call for more frequent applications or advanced formulations, which add cost. Encapsulation, nanoparticle carriers and microbial delivery systems are being developed to address these limits, but they also add regulatory complexity.
Regulatory Uncertainty and Uneven Approval Pathways
Outside the U.S., regulatory pathways for sprayable dsRNA products are still taking shape. At the time of writing, no dsRNA active substance has been approved at EU level under Regulation (EC) No 1107/2009. Belgium’s emergency authorisation of an RNA-based spray in 2026 was a national, time-limited measure. China’s ICAMA issued draft data requirements for RNA pesticide registration in April 2026, and Brazil is reviewing its first RNA-based spray registration filing. Data requirements for non-target organism testing, environmental fate and off-target sequence analysis can differ between jurisdictions. This raises the cost and time of multi-country registration. For plant-incorporated products, the GM regulatory framework adds further barriers in regions where cultivation of GM crops is restricted.
Cost Competitiveness and Grower Adoption
Despite falling production costs, RNAi products often carry a price premium over generic synthetic insecticides and fungicides, which are widely available at low cost in most major agricultural markets. Growers in price-sensitive row-crop markets need clear evidence of consistent field performance, compatibility with existing spray programmes and a return on investment before they switch. Narrow-spectrum products also require more precise pest monitoring and may need to be paired with other products to control the full pest complex, which adds complexity to crop management decisions.
Challenge: Intellectual Property and Freedom to Operate
Patents covering RNAi sequences, production methods and delivery systems are held by many companies and research institutions. New entrants must work carefully to secure freedom to operate, and cross-licensing agreements are becoming more common. The ability to design sequences against new target genes, and to protect them, is becoming a key competitive asset.
Challenge: Resistance to RNAi Itself
Laboratory studies have shown that pests can develop resistance to RNAi, for example through reduced dsRNA uptake in the gut. Resistance management will need careful stewardship: rotating target genes, stacking with other modes of action, maintaining refuges for plant-incorporated traits, and monitoring field populations. Losing the efficacy of early products through poor stewardship would harm confidence in the whole category.
Trend: Stacking RNAi with Other Modes of Action
Trait developers are combining RNAi with Bt and novel non-Bt proteins to create multi-mode-of-action stacks for durable corn rootworm control. Bayer’s MON 95275 event, which combines two insecticidal proteins with DvSnf7 dsRNA, was approved by Brazil’s CTNBio in April 2023, registered by the EPA in combination with MON 88017 in March 2025, and deregulated by USDA APHIS in March 2026. Corteva’s DP23211, which combines DvSSJ1 dsRNA with the IPD072Aa protein, was registered by the EPA in September 2024. Similar combination strategies are expected for sprayable products, which can be paired with biologicals or conventional chemistry.
Trend: Advances in Formulation and Encapsulation
Formulation is becoming a key point of competition. Developers are investing in encapsulation (for example, within microbial cell walls or engineered particles), adjuvants that improve leaf adhesion and uptake, and microbial production systems that deliver dsRNA inside inactivated cells. These technologies aim to extend field persistence, improve activity against less sensitive pests and reduce application rates. AgroSpheres’ AgriCell platform, Renaissance BioScience’s yeast-based approach and SenseUP’s Corynebacterium-based encapsulation are examples.
The RNAi biopesticides value chain has four main stages. At each stage, value is created through technology and intellectual property as well as through physical production.
Raw materials and inputs: Key inputs include nucleotide triphosphates (NTPs) or nucleotide monophosphates, polymerase and other enzymes, DNA templates, microbial production strains (such as bacteria and yeast), fermentation media, purification consumables, and formulation inputs such as adjuvants, stabilisers and encapsulating materials. For plant-incorporated products, the key inputs are elite crop germplasm, transformation vectors and trait genetics. Sequence design and bioinformatics capabilities are an equally important intangible input.
Manufacturing and product development: dsRNA is produced by cell-free enzymatic synthesis or microbial fermentation, then purified, formulated and, in some cases, encapsulated. Product development involves target gene selection, laboratory and greenhouse efficacy testing, field trials, and the generation of regulatory dossiers covering human health, non-target organisms and environmental fate. For plant-incorporated products, this stage includes event development, trait stacking, regulatory approvals in cultivation and import markets, and seed production.
Distribution and channels: Sprayable products reach growers through agricultural distributors, retailers and crop advisers, often through partnerships with established crop protection companies that hold the market access. Bee-health products are distributed through beekeeping supply channels. Plant-incorporated RNAi traits reach the market within seed sold by the trait owner’s brands, or through licences to independent seed companies.
End users: End users include row-crop growers (corn), potato and vegetable growers, vineyards, fruit and specialty-crop producers, tobacco growers, commercial beekeepers, and forestry managers. Agronomists, cooperatives and food-chain stakeholders influence purchase decisions through resistance-management recommendations and residue requirements.
RNAi biopesticides are regulated under two separate types of framework. Sprayable dsRNA products are regulated as pesticides or plant protection products. Plant-incorporated RNAi traits are regulated both under pesticide law (in the U.S., as plant-incorporated protectants) and under biotechnology or GMO law. The OECD has published guidance on the environmental risk assessment (2020) and the human health risk assessment (2023) of externally applied dsRNA-based pesticides, which supports a shared approach across member countries.
The U.S. is currently the most advanced market from a regulatory standpoint. The EPA has registered RNAi plant-incorporated protectants for corn rootworm since 2017, the sprayable dsRNA insecticide ledprona in December 2023, the RNAi-based potato virus Y protection trait in BG25 potato in July 2025, and the Varroa mite product vadescana in September 2025. In Europe, products may currently reach growers only through national emergency authorisations while active substance approvals are assessed. In China, the April 2026 draft data requirements are an important step towards a dedicated registration pathway for RNA pesticides.
Mar 2022: Bayer Crop Science; Regulatory approval; Received U.S. EPA approval for the traits in VT4PRO with RNAi Technology, its below-ground and above-ground corn insect control product.
Mar 2022: Corteva Agriscience; Product launch; Unveiled Vorceed Enlist corn, offering six insect modes of action including RNAi for below-ground corn rootworm control.
Mar 2023: Corteva Agriscience; Product launch; Announced the commercial launch of Vorceed Enlist corn products, with initial availability through the Corteva Horizon Network.
Apr 2023: Bayer Crop Science; Regulatory approval; Brazil’s CTNBio approved commercial release of MON 95275 maize, which combines two insecticidal proteins with DvSnf7 dsRNA.
Jul 2023: GreenLight Biosciences; Acquisition; Completed its take-private merger with Fall Line Endurance Fund, backed by USD 52.075 million of financing.
Nov 2023: Renaissance BioScience; Partnership; Signed a joint development agreement with Certis Belchim to develop and commercialise an RNAi biopesticide.
Dec 2023: AgroSpheres; Funding; Closed a USD 25 million Series B round with participation from investors including FMC Ventures.
Dec 2023: GreenLight Biosciences; Regulatory approval; The U.S. EPA registered ledprona (Calantha), the first sprayable dsRNA pesticide, for Colorado potato beetle control in potatoes.
Jan 2024: GreenLight Biosciences; Product launch; Announced first commercial sales of Calantha for the 2024 potato season.
May 2024: FMC Corporation; Partnership; Entered a multi-year research and co-development agreement with AgroSpheres for RNA-based bioinsecticides.
Sep 2024: Corteva Agriscience; Regulatory approval; The U.S. EPA registered the DP23211 maize plant-incorporated protectant containing DvSSJ1 dsRNA.
Feb 2025: GreenLight Biosciences; Expansion; Secured a loan of up to EUR 35 million from the European Investment Bank for research, registration and manufacturing of RNA-based products in Spain.
Mar 2025: Bayer Crop Science; Regulatory approval; The U.S. EPA registered the MON 95275 × MON 88017 maize plant-incorporated protectant, which includes DvSnf7.1 dsRNA.
Apr 2025: GreenLight Biosciences; Funding; Raised a USD 25 million Series C round from Just Climate.
May 2025: SenseUP; Funding; Closed a EUR 2.4 million seed round to develop encapsulated dsRNA crop protection products, later extended to EUR 3 million.
May 2025: Renaissance BioScience; Funding; Received Agriculture and Agri-Food Canada AgriScience Program funding of CAD 829,708 for yeast-based RNAi delivery research.
Jun 2025: Genolution; Partnership; Signed a memorandum of understanding with SB Sungbo on dsRNA-based crop protection agents.
Jul 2025: J.R. Simplot Company; Regulatory approval; The U.S. EPA registered BG25 potato with RNAi-based potato virus Y protection.
Sep 2025: GreenLight Biosciences; Regulatory approval; The U.S. EPA registered vadescana for Varroa mite control in honeybee colonies, marketed as Norroa through Mann Lake.
Oct 2025: GreenLight Biosciences; Regulatory filing; Filed for registration of the RNA-based fungicide erysichrona for grape powdery mildew in Brazil.
Oct 2025: Corteva Agriscience; Restructuring; Announced its intention to separate its seed and crop protection businesses into two independent companies.
Mar 2026: Bayer Crop Science; Regulatory approval; USDA APHIS granted non-regulated status to MON 95275 maize.
Apr 2026: Silicon Gene Technologies; Regulatory; Its dsRNA virucide tomovircona (technical and suspension concentrate products) was included in an ICAMA pesticide registration batch in China.
May 2026: GreenLight Biosciences; Regulatory approval; Belgium granted an emergency authorisation for Calantha against Colorado potato beetle, the first use of RNA crop protection in the EU.
Sep 2026: FMC Corporation; Product development; Advanced two RNA bioinsecticide candidates developed with AgroSpheres into global field trials in the U.S., Brazil and Asia.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 109 companies operating in the RNAi Biopesticides Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
FMC Corporation is a Philadelphia-based, pure-play crop-protection company and one of the tier-one research-based agrochemical innovators, alongside Syngenta, Bayer, BASF and Corteva. It discovers, develops, manufactures and markets insecticides, herbicides, fungicides and "Plant Health" products (biologicals, crop nutrition, seed treatment) through distributors, retailers, cooperatives and, increasingly, direct-to-grower channels in Brazil. Its economic franchise was built on the diamide insecticides acquired from DuPont in 2017: Rynaxypyr® (~USD 0.8bn of FY2025 sales) and Cyazypyr® (~USD 0.4bn). Both have now lost core patent protection. FMC is therefore in a deep transition. FY2025 revenue fell to USD 3.47bn and the company booked a USD 2.24bn GAAP loss. It has cut the dividend 86%, fallen to junk credit status, and in 2026 raised capital through asset sales, a Corteva licence and a 20% equity stake sale to Tessenderlo Group. The equity case now rests on four new-mode-of-action active ingredients: Isoflex®, fluindapyr, Dodhylex™ and rimisoxafen. --- ### Company's own description (FY2025 10-K, paraphrased) FMC describes itself as a global agricultural sciences company that supplies farmers with innovative solutions to increase the productivity and resilience of their land, and states that it operates in a single business segment. It develops, markets and sells all three major classes of crop-protection chemicals (insecticides, herbicides and fungicides), together with biologicals, crop nutrition and seed-treatment products grouped as "Plant Health." The 10-K calls FMC a "tier-one leader" in agrochemicals, positioned through technology, geographic balance and crop diversity. For 2026 it sets four operational priorities: - strengthening the balance sheet; - improving competitiveness of the core portfolio; - managing the post-patent Rynaxypyr® transition; - supporting the growth of new active ingredients. ### Value-chain position FMC is a discovery-to-formulation innovator that relies heavily on outsourcing. It owns large-scale AI plants in: - Mobile, Alabama (USA) - Manati, Puerto Rico - Jinshan, China - Rønland, Denmark - Panoli, India It also sources "critical intermediates and finished products" largely from third parties in China and India (10-K FY2025 risk factors). Downstream, it sells through: - distributors, retailers and cooperatives in all four regions; - direct sales to large growers in Brazil, an expanding channel cited as a Q4 FY2026 growth driver; - alliance partners, including diamide partners on "cost-plus" contracts. ### Customer types and end-markets Customers are agricultural distributors and retailers, co-ops, large growers (Brazil), and other agrochemical companies that buy diamide AI under supply contracts. End-markets are row crops (soybean, corn, cotton, sugarcane, rice, cereals) and specialty crops (fruits, vegetables, tree nuts). Non-crop uses (pest control, turf) were largely exited with the sale of the Global Specialty Solutions business in November 2024. Demand is seasonal. Northern-hemisphere demand runs March–September, weighting Q1/Q2. Southern-hemisphere demand runs July–February, weighting Q3, Q4 and Q1 (10-K FY2025). ### Independent characterization FMC is a mid-sized research-based agrochemical company. It has a disproportionately concentrated franchise: the diamides were roughly 35% of FY2025 GAAP revenue (USD ~1.2bn of USD 3.47bn). The company is now caught between generic-driven price deflation on its legacy molecules and a still-sub-scale new-AI portfolio (USD ~200M in FY2025). It also faces an unusually leveraged balance sheet for a company of its size. Its strategy has shifted from "growth and returns" (2021–2023) to "survival and re-base" (2025–2026): - monetize IP through partners (Corteva); - shrink the manufacturing footprint (Project Foundation); - exit structurally unprofitable markets (India commercial); - recapitalize via a strategic minority investor (Tessenderlo).
Company Headquarters: Indianapolis, US Founded: 1989 Workforce: ~21,100 Company Working: Corteva Agriscience develops, manufactures, and markets a wide range of products, including seeds and traits, crop protection, software, and digital solutions, seed treatments, forages, inoculants, vegetation management, pasture management, turf and ornamental, urban pest management, and oil. It is directly present in more than 50 countries and covers all major regions such as North America, Asia-Pacific, Latin America, Europe, and the Middle East & Africa. Corteva Agriscience is a subsidiary of Dow Chemical Company. Hence, the provided financial information is of the Dow Chemical Company.
RNAissance Ag is an early-stage US agricultural biotechnology company developing sprayable, RNA interference (RNAi)-based biopesticides. Spun out of the Donald Danforth Plant Science Center in St. Louis and incubated by venture developer TechAccel, it holds an exclusive license to RNAi technology discovered at the Danforth Center and designs double-stranded RNA (dsRNA) molecules that silence essential genes in a single target insect species, aiming to kill the pest while sparing pollinators, beneficial insects, animals and people. Its lead programs have targeted lepidopteran pests — notably diamondback moth and fall armyworm — with Colorado potato beetle among additional targets. Through its 2020 acquisition of RNAgri, it also owns a dsRNA manufacturing platform aimed at the low per-gram cost required for broad-acre spraying. The company is pre-commercial, pre-revenue as far as public sources show, and operates in a nascent category whose first sprayable product (a competitor's) was registered by the US EPA only in December 2023. --- ### What the company does RNAissance Ag develops topically applied (sprayable) RNAi insecticides. The scientific principle is that a dsRNA molecule, when ingested by an insect, is processed by the insect's own RNAi machinery into small interfering RNAs that suppress expression of a targeted essential gene, leading to feeding cessation and death. Because the sequence is matched to a specific gene in a specific species, the company's products are designed to be highly selective, non-toxic to non-target organisms, and biodegradable. Company releases (October 2022) state that its designs can also be used as pesticidal traits in crop seeds, i.e., expressed in-plant rather than sprayed. The company has two technology pillars: 1. **Target discovery and product design** — sequences licensed from the Danforth Center and the company's own discovery work, including (per the Danforth Center's 2019 IN2 profile) novel mechanisms to target lepidopteran pests across a range of crops, and a high-throughput screening platform to identify biological insecticides. 2. **dsRNA manufacturing** — the RNAgri platform acquired in June 2020, aimed at producing dsRNA at cost, yield and purity suitable for field application. ### Company's own description RNAissance Ag does not publish an annual report. Its most consistent self-description, repeated in the October 2022 CEO-appointment release, is that its primary focus is developing sprayable RNAi pesticides against pests such as diamondback moth, fall armyworm and several others, designed to be highly specific to the target pest, non-toxic to other organisms, and biodegradable, with additional applicability as seed traits. The 2019 IN2 cohort announcement described it as a biotechnology startup focused on delivering RNA-based insecticides for crop protection. ### Business model and revenue model Product vs. service vs. subscription vs. licensing revenue mix: not publicly disclosed. ### Value-chain position RNAissance sits at the discovery/development end of the crop-protection value chain: target identification → dsRNA design → manufacturing → formulation (with partners such as AgroSpheres) → regulatory registration (US EPA under FIFRA) → distribution to growers. It has internalized manufacturing (RNAgri) but has not been shown to own formulation, regulatory or distribution capabilities at scale. ### Customer types and end-markets Ultimate customers would be growers (via distributors/retailers) and potentially seed and crop-protection companies as licensees. ### Independent characterization RNAissance Ag is best understood as a small, regionally anchored (St. Louis/Kansas City) venture-development portfolio company whose public profile peaked in 2019–2022. Its technology thesis has been validated at the category level — the EPA's December 2023 registration of GreenLight Biosciences' Calantha (ledprona) proved that a sprayable dsRNA insecticide can be registered in the US — but no public source reviewed shows RNAissance itself having filed for or obtained a registration, closed a priced institutional round, or announced a commercial partnership since 2022. The absence of public newsflow from 2023 through October 2026 is itself an important finding.
3 interactive charts drawn from the RNAi Biopesticides Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global RNAi Biopesticides Market By Target Pest
Global RNAi Biopesticides Market By Application Method
Global RNAi Biopesticides Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
